pharma · Acute myeloid leukemia · Juvenile idiopathic arthritis
Istituto Gentili Italia
Istituto Gentili S.r.l.
Istituto Gentili Italia clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Via San Giuseppe Cottolengo, 15, Milano, Lombardia 20143, IT
- Founded
- 1917
- Employees
- 121
- Programs
- 50
- Drugs
- 114
- Patents
- 0
Istituto Gentili Italia projects
8 ClinicalTrials.gov programs sponsored by Istituto Gentili Italia.
Istituto Gentili Italia has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
IRST204.07
Istituto Gentili S.r.l.
Acute myeloid leukemia
1 trial -
Intrarosa 6.5 mg pessary
Istituto Gentili S.r.l.
Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome).
1 trial -
MOTOR
Istituto Gentili S.r.l.
patients scheduled to undergo elective surgical procedures with general anesthesia
1 trial -
PAPA-Can
Istituto Gentili S.r.l.
PAPA syndrome
1 trial -
PLACEBO for amyotrophic lateral sclerosis
Istituto Gentili S.r.l.
amyotrophic lateral sclerosis
1 trial -
PRINCE
Istituto Gentili S.r.l.
End Stage Kidney Disease on chronic dialysis therapy
1 trial -
RC 4/24 TREAT-UTI
Istituto Gentili S.r.l.
Urinary Tract Infections
1 trial -
Wegovy solution for Diabetes Mellitus, Cardiovascul…
Istituto Gentili S.r.l.
Diabetes Mellitus, Cardiovascular disease, Overweight (BMI ≥27 kg/m²), Obesity (BMI≥30kg/m2)
1 trial
Frequently asked questions
How many clinical projects does Istituto Gentili Italia have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.